治疗非酒精性脂肪肝：奥贝胆酸前景佳

Obeticholic acid tablets were approved for marketing in the United States in May 2016. The original research company is Intercept Pharmaceuticals, with the trade name OCALIVA. The approved indication is the treatment of primary biliary cholangitis (PBC). The active ingredient of the tablet is obeticholic acid, which is a semi-synthetic derivative of the human primary bile acid chenodeoxycholic acid (CDCA). It is a selective farnesoid derivative receptor (FXR) agonist that is 100 times more active than CDCA and has anti-cholestasis and hepatoprotective properties.

Professor Brent and his team from the Department of Gastroenterology and Hepatology at Saint Louis University conducted a multi-center, randomized, placebo-controlled trial FLINT to evaluate the efficacy of obeticholic acid in non-cirrhotic, non-alcoholic steatohepatitis (NASH). The results were recently published in The Lancet. This study shows that obeticholic acid treatment can benefit NASH patients in multiple aspects of biochemistry and histology, and may play a certain role in preventing the progression of the disease to cirrhosis.

In the experiment, it was fatigue, rash, joint pain, thyroid dysfunction, skin itching, dizziness, constipation, eczema, oropharyngeal pain, abdominal pain, etc. Finally, the editor of Medical Companion Travel would like to solemnly tell everyone that if the patient is currently taking the drug obeticholic acid, he must remember the doctor's instructions and take the medication according to the doctor's instructions. Only by carefully following the doctor's instructions can the drug itself be used to its greatest extent.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.